Tevogen AI

Applying proprietary predictive technologies to accelerate drug development and advance toward predicting the proteome for any protein–HLA combination.

[Ryan Saadi, Founder, TEVOGEN @DrRyanSaadi]

The most powerful pharmacy in the world isn’t on a street corner. It’s already inside our veins. @TevogenBio - #Tcell
🌐 https://t.co/9FOwy8XEKJ $TVGN

[Tevogen Bio @TevogenBio]

📰 https://t.co/0Rj0z1Tq5A

“Tevogen’s evaluation of potential MSO and CRO acquisitions reflects a disciplined approach to building revenue-generating capabilities that may support long-term financial self-sufficiency,” said Kirti Desai, Chief Financial Officer at Tevogen. “With approximately $100 million in potential combined annual revenue under evaluation, we believe these opportunities could represent an important step toward strengthening the Company’s financial foundation while remaining aligned with our mission to make healthcare more affordable and accessible.”

$TVGN #HealthcareEnterprise #StrategicAcquisitions #Revenue @DrRyanSaadi

[Tevogen Bio @TevogenBio]

“Bridging medical science and artificial intelligence to develop affordable, lifesaving therapies isn’t just innovation, it’s the future of medicine.” - Ryan Saadi, @CEO_TEVOGEN_BIO

$TVGN #JPMorganHealthcareConference #affordable #accessible #celltherapy #ICYMI

[Tevogen Bio @TevogenBio]

At JPM43 Mittul Mehta, @Head_TevogenAI and @drhew
Chief Medical Officer & VP of Healthcare at
@Microsoft discussed AI in Biopharma: Next Frontier of Medical Innovation

$TVGN $MSFT @DrRyanSaadi #Healthcare #ArtificialIntelligence #AI #Innovation #ICYMI

[Tevogen Bio @TevogenBio]

📰 https://t.co/tMwk9ax3lO

“Advancing PredicTcell toward completion marks an important milestone in our AI strategy,” said @Head_TevogenAI Mittul Mehta, “As we begin exploring commercial pathways, our focus remains on maintaining scientific rigor while building scalable tools that can extend the impact of our platform beyond internal use.”

$TVGN #PredicTcell #ArtificialIntelligence #MachineLearning #DrugDiscovery #Immunotherapy

[Tevogen Bio @TevogenBio]

🔗 https://t.co/CvvZCoRGzs

As part of our ongoing work on PredicTcell™, we’ve been leveraging scalable data infrastructure to process and analyze hundreds of millions of peptide sequences across diverse disease areas.

This recent feature by @databricks highlights elements of that journey, how modern data architecture can support complex biological modeling and help move from static datasets toward adaptive, continuously learning systems.

Thank you, Databricks, for supporting @TevogenAI’s journey toward what we consider the “holy grail”: 𝘵𝘩𝘦 𝘢𝘣𝘪𝘭𝘪𝘵𝘺 𝘵𝘰 𝘱𝘳𝘦𝘥𝘪𝘤𝘵 𝘵𝘩𝘦 𝘱𝘳𝘰𝘵𝘦𝘰𝘮𝘦 𝘧𝘰𝘳 𝘢𝘯𝘺 𝘨𝘪𝘷𝘦𝘯 𝘤𝘰𝘮𝘣𝘪𝘯𝘢𝘵𝘪𝘰𝘯 𝘰𝘧 𝘱𝘳𝘰𝘵𝘦𝘪𝘯 𝘢𝘯𝘥 𝘏𝘓𝘈 𝘵𝘺𝘱𝘦.

$TVGN #ArtificialIntelligence #MachineLearning #Bioinformatics #DataEngineering #AIinHealthcare

[Tevogen Bio @TevogenBio]

https://t.co/VM3narVLzO at @FABConSQLCon

Tevogen CIO and @Head_TevogenAI, Mittul Mehta, speaking to building an AI-ready data foundation to power precision immunotherapy, transforming complex scientific data spanning millions of protein sequences and hundreds of millions of peptides.

$TVGN $MSFT #AI #Biotech #FabCon #Microsoft #PrecisionMedicine #BigData #Analytics

[Mittul Mehta @Head_TevogenAI]

Honored to see https://t.co/vkk1FCR3Vt recognized by @Microsoft at #FabCon as an ISV. AI in biotech is shifting from models to systems—continuous learning, real-world feedback, and scale. Just getting started. #AI #Biotech $TVGN $MSFT @arunulag

[Tevogen Bio @TevogenBio]

📰 https://t.co/1HfTi2RHVs

@Head_TevogenAI Mittul Mehta, stated, “Our goal is to reduce trial-and-error in immunotherapy design and ultimately predict the proteome for any given combination of protein and HLA type. As our prediction quality improves, we believe we can meaningfully increase success rates while lowering development risk. That combination has the potential to create significant long-term value.”

@TevogenAI $TVGN #PredicTcell #artificialintelligence #DrugDiscovery #immunotherapy

[Mittul Mehta @Head_TevogenAI]

"What are you actually seeing from PredicTcell?" Early beta: Recall up to 92%, Precision to 48%, true positives rising. Built on 665M+ peptides, solving a real gap in precision immunotherapy. Preliminary results, but I'm comfortable sharing them. $TVGN #Biotech #AI

[Tevogen @Tevogen]

📰 https://t.co/NbkjzEnqZU

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus

$TVGN #Sciometrix #Clinicus #HealthcareTechnology #Revenue #Strategy @TevogenBio @TevogenAI

[Tevogen Bio @TevogenBio]

📢 From Mittul Mehta, Tevogen CIO and @Head_TevogenAI.

Most companies celebrate going public. We used it as a starting gun.

Two years ago, Tevogen went public at Nasdaq - A day I’ll always remember for the energy, the optimism, and the responsibility that comes with running a public company.

Then the morning after, the real work began.

When we stood up https://t.co/VM3narVLzO, the conviction was clear: AI wasn't going to be a support function. It was going to be a frontier capability that fundamentally changed how we read, understand, and act on complex biological data.

Simple in conviction. Hard in execution.

Since then, the teams have gone from thesis to tangible: 655 million unique peptides, models scaling nearly 20x between training cycles, and a platform built to compound as the science advances. None of that came from moving fast for its own sake. It came from disciplined decisions — what to build, what to buy, and where partnerships produced durable leverage.

What excites me most isn't what's already been achieved… It's what's next.

As we close out beta training for PredicTcell™ and move into AdapTcell™, the platform is transitioning from experimentation to operational reality. The feedback loop between our AI and biology teams is tightening with every cycle and increasing learning velocity.

Two years on, the work feels less about celebration and more about momentum, which is exactly where it should be.

For leaders building AI at scale: where are you seeing the biggest gap between experimentation and execution?

#AIinBiotech #LifeSciences #TechnologyStrategy #Leadership $TVGN #Board #CIO #AIPlatforms #PublicCompany #BoardPerspective #TechnologyLeadership

[Tevogen Bio @TevogenBio]

📰 https://t.co/XA3uCuHRbm

“Tevogen began as a T cell therapy biotech and has since evolved into a diversified healthcare company, including a scalable healthcare AI initiative. The Company’s goal is to launch at least four blockbuster products by 2030, and to pursue revenue generation in 2026 through our current programs, potential asset acquisitions, and joint ventures.” - @DrRyanSaadi

$TVGN #CorporateGovernance #EquityIncentives #RevenueFocus #GrowthStrategy #HealthcareAI

[Tevogen Bio @TevogenBio]

📢 From Mittul Mehta, Tevogen CIO and Head of @TevogenAI

Reflecting on the past year at https://t.co/VM3narWjpm, I’m proud to share a snapshot of what we’ve built, and where we’re headed.

Through strategic partnerships with @Databricks and @Microsoft, our team has developed a highly curated dataset spanning ~24 million proteins. Using our proprietary data refinement processes, this has expanded into a library of 655 million unique peptides, with nearly 16 billion data points across 12 clinical conditions and the known human genome.

By cross-referencing this work with 37 million expert scientific articles, we’ve been able to enrich our datasets, uncover critical biochemical properties of amino acid chains, identify key anchor residues, and sharpen HLA specificity at scale.

On the modeling front, our PredicTcell™ journey has accelerated rapidly. While the alpha model was trained on ~100,000 data points and served as an important benchmark, the beta version now incorporates 1.8 million data points, representing nearly a 20-fold scale-up.

As we wrap the PredicTcell™ beta and begin training AdapTcell™, I’m excited to continue sharing progress as https://t.co/VM3narWjpm advances toward what many consider the Holy Grail of immunology: Predicting the proteome for any given protein–HLA combination.

More to come.

@drhew @hoifungpoon @TevogenAI @Microsoft @databricks

$TVGN #TevogenAI #AIinBiotech #ComputationalBiology #Immunology #PrecisionMedicine #MachineLearning

[Tevogen Bio @TevogenBio]

🎙Q&A with Tevogen CEO🎙

Q. As Tevogen continues to build long-term value, how do you think about capital allocation and sharing that success with shareholders over time?

A. I’ve always believed that when a company succeeds, shareholders should share in that success. I am supportive of the Board evaluating a potential one-time special cash dividend in the context of future performance, which is obviously subject to Board approval. I personally believe returning capital to shareholders is critical for long term value creation for any high growth enterprise. - @DrRyanSaadi

$TVGN #affordable #accessible #celltherapy #JPM2026 @Tevogen @TevogenAI

[Tevogen Bio @TevogenBio]

📰 https://t.co/NRKT8MnuRJ

🔹Platform & Manufacturing Progress: Advanced the ExacTcell™ platform in 2025, improving CTL yield, consistency, and throughput while progressing toward in-house GMP manufacturing capabilities.

🔹Pipeline Expansion: Expanded the CTL pipeline across multiple viral and oncology indications, including EBV-associated lymphomas, chronic hepatitis B, and HPV-related cancers, supported by @TevogenAI.

🔹Execution & Value Creation: Achieved key scientific and operational milestones positioning Tevogen as a scalable, multi-program cell therapy organization with a foundation for long-term value creation.

$TVGN #affordable #accessible #celltherapy #JPM2026

[Tevogen @Tevogen]

Meet Tevogen leadership at the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from January 12-15, 2026.
All meeting requests are coordinated via [email protected]

$TVGN @TevogenBio @TevogenAI #JPM26 #JPM2026 #affordable #accessible #celltherapy

[Tevogen Bio @TevogenBio]

“Dr. Patton’s leadership and scientific vision have played a pivotal role in shaping Tevogen’s foundation,” said @DrRyanSaadi, Founder & CEO of @Tevogen. “His legacy at Yale reinforces the strength of the Company’s mission during a period of significant momentum.”

📰 https://t.co/9Zfl4hZ9WJ

@Tevogen @TevogenAI @Yale @YaleSPH @YaleMed

[Tevogen Bio @TevogenBio]

🍂 As we approach Thanksgiving, we cannot think of a better time to express our immense gratitude to each of you for embracing our mission.
Wishing you and those you hold dearest a Happy Thanksgiving, filled with health, love, and gratitude.🍃

$TVGN

[Ryan Saadi, Founder, TEVOGEN @DrRyanSaadi]

American patients have waited long enough. America needed a healthcare enterprise that didn’t require billions. They said it was impossible. They were wrong. 5.5 years. ~$40M. Founders still own the majority and the mission. Meet Tevogen 🇺🇸 — a purpose-driven healthcare enterprise built by a team with >300 years of combined experience across healthcare, economics, AI, and yes - investment banking and finance.

It started with so-called “biotech” product development, whatever that word even means anymore beyond marketing and outdated financial literacy.

Simple translation for anyone still using 1970s vocabulary:

🔹Pharma = chemistry
(such as Na + Cl → NaCl: normal saline. In other words, salt.)
🔹#Biotech = engineering living systems, such as cell therapies and antibodies, which, ironically, now make up the majority of most “#pharma” pipelines and portfolios.

@TevogenAI : A pioneering AI initiative of our era - rewriting discovery, delivery, and democratization of precision medicine, powered by collaborations with tech giants @Microsoft & @databricks Tevogen Generics is our commitment to affordable, accessible medicine for American patients at scale. And yes, if we can process trillions (that’s a T) of data points through large-scale AI architectures and make sense of them, we can detect patterns.

Debate me. Advanced medicine isn’t just innovation — it is our national security, and that’s not negotiable, regardless of thesis. And, our #Tcell therapy pipeline is more robust than ever. More at https://t.co/uj35JpDpge

#AIinMedicine #PrecisionMedicine #HealthTech #MAHA $TVGN #oncology #LongCOVID #EBV